4 recruiting, 3 completed, 1 unknown, 1 withdrawn. 9 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Completed 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Localized Prostate Cancer: new trials by email Literature Review of Localized Prostate Cancer trials Research Report on Localized Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer Stereotactic Body Radiotherapy (SBRT) Monotherapy, External Beam Radiotherapy (EBRT) Backbone, High-Dose-Rate Brachytherapy Boost - Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy | Phase 2 / Phase 3 | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 1000 | 2026-03-19 | 2026-07-21 |
| 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy 18F-DCFPyL - Localized Prostate Cancer | Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-08-31 | 2026-10-16 |
| Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer carbon ion irradation, Carbon Ion Irradiation With SIB - Localized Prostate Cancer | Phase 2 | Recruiting | Shanghai Proton and Heavy Ion Center | 140 | 2020-10-15 | 2021-11-15 |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Atezolizumab, Tocilizumab, Etrumadenant - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Recruiting | David Oh | 68 | 2019-10-30 | 2026-06-04 |
| Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. TOOKAD Soluble 4 mg/kg - Localized Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 50 | 2017-10-02 | 2026-09-10 |
| A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Enzalutamide, Abiraterone acetate, Prednisone - Prostate Cancer, Localized Prostate Cancer | Phase 2 | Withdrawn | Kenneth Pienta, MD | 2014-09-01 | 2015-01-26 | |
| Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer Ad5-SGE-REIC/Dkk3 - Localized Prostate Cancer | Phase 1 / Phase 2 | Completed | Momotaro-Gene Inc. | 28 | 2013-10-01 | 2020-09-04 |
| Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant. Focal brachytherapy - Localized Prostate Cancer | Phase 2 | Completed | Institut Claudius Regaud | 18 | 2013-08-23 | 2026-04-14 |
| Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue Organic Germanium, Placebo - Localized Breast Cancer, Localized Prostate Cancer | Phase 2 | Unknown | Arizona Oncology Services | 101 | 2005-04-01 | 2011-06-23 |
Prostatic Neoplasms (6) · Adenocarcinoma (1) · Breast Neoplasms (1) · Fatigue (1)
Genital Diseases (6) · Genital Diseases, Male (6) · Genital Neoplasms, Male (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Prostatic Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Breast Diseases (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Dutasteride (1) · Prednisone (1) · Radiosurgery (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · atezolizumab (1) · enzalutamide (1) · padeliporfin (1) · tocilizumab (1)
Affidea Nu-med Center of Oncological DIagnostics and Therapy (1) · Arizona Oncology Services (1) · David Oh (1) · Institut Claudius Regaud (1) · Kenneth Pienta, MD (1) · Momotaro-Gene Inc. (1) · National Cancer Institute (NCI) (1) · Shanghai Proton and Heavy Ion Center (1) · Steba Biotech S.A. (1)
United States (6) · China (1) · France (1) · Poland (1)
Brian J Miles, MD, FACS (1) · Christopher J Kane, MD (1) · David Oh, MD, PhD (1) · Deborah E Citrin, M.D. (1) · Emily Grade, MD (1) · Jonathan Coleman, MD (1) · Kenneth J Pienta, MD (1) · Mateusz Bilski, MD PhD (1)